Currently out of the existing stock ratings of Kalpit Patel, 71 are a BUY (82.56%), 15 are a HOLD (17.44%).

Kalpit Patel

Work Performance Price Targets & Ratings Chart

Analyst Kalpit Patel, currently employed at WOLFE, carries an average stock price target met ratio of 37.52% that have a potential upside of 32.13% achieved within 121 days. Previously, Kalpit Patel worked at CREDIT SUISSE, 2924.0, B. RILEY.

Kalpit Patel’s has documented 154 price targets and ratings displayed on 24 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on KYMR, Kymera Therapeutics at 29-Jun-2026.

Wall Street Analyst Kalpit Patel

Analyst best performing recommendations are on BCYC (BICYCLE THERAPEUTICS LTD).
The best stock recommendation documented was for VRDN (VIRIDIAN THERAPEUTICS) at 9/11/2024. The price target of $22 was fulfilled within 2 days with a profit of $2.2 (11.11%) receiving and performance score of 55.56.

Average potential price target upside

of $132.88 (86.44%) on MGTA (MAGENTA THERAPEUTICS).
of $89.95 (66.81%) on INKT (MINK THERAPEUTICS).
of $13.74 (28.9%) on KYMR (KYMERA THERAPEUTICS).

BCYC Bicycle Therapeutics Ltd INFI Infinity Pharmaceuticals INKT Mink Therapeutics KYMR Kymera Therapeutics MGTA Magenta Therapeutics RIGL Rigel Pharmaceuticals FBRX Forte Biosciences ALLO Allogene Therapeutics ENTX Entera Bio Ltd INAB In8bio VINC Vincerx Pharma MRTX Mirati Ther DERM Journey Medical Corp GERN Geron VRDN Viridian Therapeutics SNDX Syndax Pharmaceuticals LBPH Longboard Pharmaceuticals CRBP Corbus Pharmaceuticals PDSB PDS Biotechnology Corp VSTM Verastem XFOR X4 Pharmaceuticals OVID Ovid Therapeutics AVBP ArriVent BioPharma, Common Stock MG Mistras Group

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jeffrey Hung (MORGAN STANLEY)